GE HealthCare Technologies Management

Management Kriterienprüfungen 0/4

GE HealthCare Technologies' CEO ist Pete Arduini , ernannt in Dec 2022, hat eine Amtszeit von 1.5 Jahren. Die jährliche Gesamtvergütung beträgt $24.51M , bestehend aus 5.1% Gehalt und 94.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.001% der Aktien des Unternehmens, im Wert von €415.38K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.4 Jahre bzw. 1.4 Jahre.

Wichtige Informationen

Pete Arduini

Geschäftsführender

US$24.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	5.1%
Amtszeit als Geschäftsführer	1.8yrs
Eigentum des Geschäftsführers	0.003%
Durchschnittliche Amtszeit des Managements	1.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Pete Arduini im Vergleich zu den Einnahmen von GE HealthCare Technologies verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$25m	US$1m	US$1b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	US$10m	US$1m	US$2b

Vergütung im Vergleich zum Markt: PeteDie Gesamtvergütung ($USD24.51M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD5.00M).

Entschädigung vs. Einkommen: PeteDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Pete Arduini (59 yo)

1.8yrs

Amtszeit

US$24,510,947

Vergütung

Mr. Peter J. Arduini, also known as Pete, serves as Director of Ge Healthcare since January 2023. He was a Senior Vice President at General Electric Company since January 2022. He has been President and Ch...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Peter Arduini	President	1.8yrs	US$24.51m	0.0028% $ 1.1m
James Saccaro	VP & CFO	1.3yrs	US$10.97m	0.0033% $ 1.2m
Taha Kass-Hout	Chief Science & Technology Officer	1.7yrs	US$13.87m	0.0035% $ 1.3m
Frank Jimenez	VP, General Counsel & Corporate Secretary	1.7yrs	US$7.51m	0.0047% $ 1.8m
George Newcomb	Controller & Chief Accounting Officer	1.8yrs	keine Daten	0.0012% $ 436.4k
Jahid Khandaker	Chief Information Officer	no data	keine Daten	keine Daten
Carolynne Borders	Chief Investor Relations Officer	no data	keine Daten	keine Daten
Rana Strellis	Chief Corporate Marketing & Communications Officer	no data	keine Daten	keine Daten
Adam Holton	Chief People Officer	less than a year	keine Daten	keine Daten
Thomas Westrick	President & CEO of Patient Care Solutions	4.7yrs	keine Daten	0.0014% $ 511.7k
Kevin O'Neill	President & CEO of Pharmaceutical Diagnostics	no data	keine Daten	0.0020% $ 748.7k
Roland Rott	President & CEO of Imaging	1.7yrs	keine Daten	0.0053% $ 2.0m

1.7yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: L0TDas Führungsteam des Unternehmens gilt nicht als erfahren (1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Peter Arduini	President	1.7yrs	US$24.51m	0.0028% $ 1.1m
H. Culp	Chairman	1.7yrs	US$531.65k	0.089% $ 33.3m
Risa Lavizzo-Mourey	Lead Independent Director	1.7yrs	US$456.65k	0.00023% $ 86.5k
Anne Madden	Independent Director	1.7yrs	US$401.61k	0% $ 0
William Stromberg	Independent Director	1.7yrs	US$421.58k	0% $ 0
Rodney Hochman	Independent Director	1.7yrs	US$401.61k	0% $ 0
Lloyd Howell	Independent Director	1.7yrs	US$401.65k	0% $ 0
Tomislav Mihaljevic	Independent Director	1.7yrs	US$401.65k	0% $ 0
Phoebe Yang	Independent Director	1.7yrs	US$401.65k	0% $ 0
Catherine Lesjak	Independent Director	1.8yrs	US$426.65k	0% $ 0

1.7yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrener Vorstand: L0TDie Vorstandsmitglieder gelten nicht als erfahren ( 1.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

GE HealthCare Technologies Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Insider recently sold €1.4m worth of stock

GE Healthcare Names Adam Holton as Chief People Officer

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

Recent updates

Second quarter dividend of US$0.03 announced

GE HealthCare Introduces Elevated Venue Point of Care Ultrasound Solutions and New Tablet-Based Venue Sprint

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

GE HealthCare Technologies Inc. Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments At the Point of Care At ESC 2024

GE HealthCare Announces the Publication of the MASTER Trial Results in the Peer-Reviewed Journal Anesthesia and Analgesia

Insider recently sold €1.4m worth of stock

Second quarter 2024 earnings released: EPS: US$0.94 (vs US$0.92 in 2Q 2023)

GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q2, 2024 Results on Jul 31, 2024

First quarter dividend of US$0.03 announced

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024

GE Healthcare Names Adam Holton as Chief People Officer

GE HealthCare Unveils SIGNA MAGNUS, an FDA 510(K) Pending Head-Only Magnetic Resonance (MR) Scanner Designed to Explore Advance Advancements in Neuro Science

GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

First quarter 2024 earnings released: EPS: US$0.82 (vs US$0.41 in 1Q 2023)

GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women's Health Imaging

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q1, 2024 Results on Apr 30, 2024

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

GE Healthcare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

GE HealthCare Technologies Inc. to Feature Latest Technologies in Interventional Radiology Focused on Precision Care At Sir 2024

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

Now 23% overvalued after recent price rise

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.06925 billion.

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

New minor risk - Profit margin trend

Full year 2023 earnings released

Now 29% overvalued after recent price rise

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year of 2024

GE HealthCare Technologies Inc. Receives 510(K) Clearance from the United States Food and Drug Administration for Novii™+ Wireless Patch Solution

GE HealthCare Technologies Inc. Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation

Now 20% overvalued after recent price rise

GE HealthCare Technologies Inc. to Report Q4, 2023 Results on Feb 06, 2024

GE HealthCare Technologies Inc. (NasdaqGS:GEHC) entered into definitive agreement to acquire MIM Software Inc.

Upcoming dividend of US$0.03 per share at 0.2% yield

GE HealthCare Highlights Commitment to Delivering Better Patient Experiences and Outcomes Through Deep Learning at RSNA 2023

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

GE HealthCare Technologies Inc. Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE Healthcare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released

GE HealthCare Technologies Inc. Announces to Showcase Some of the Latest Innovations Designed to Help Clinicians in the Treatment of Cardiovascular Disease At the 2023 Transcatheter Cardiovascular Therapeutics Conference

GE HealthCare Technologies Inc. to Report Q3, 2023 Results on Oct 31, 2023

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

GE HealthCare Launches Enhanced Venue Family Ultrasound Systems Featuring AI-Driven Caption Guidance

GE HealthCare Technologies Inc. Announces Cash Dividend for Third Quarter of 2023, Payable on November 15, 2023

GE HealthCare Introduces Vscan Air SL, Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients

GE HealthCare Technologies Inc. Receives FDA Clearance for Portrait Mobile, Wireless Monitoring Solution Aiding Early Detection of Patient Deterioration

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.92 (vs US$1.04 in 2Q 2022)

Upcoming dividend of US$0.03 per share at 0.1% yield

GE HealthCare Technologies Inc. to Report Q2, 2023 Results on Jul 25, 2023

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter